Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.
A recognized scientific informatics pioneer, Mr. Conway brings to Riffyn extensive experience transforming scientific data environments and analytics OAKLAND, Calif.–(BUSINESS…
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.
Transgeen in agreement with AstraZeneca to co-developfive armed oncolytic vaccinia virus candidates. Innovative oncolyticviruses resulting from this collaboration will use Transgene’sproprietary next generation viral platform Invir.IO
Myriad Genetics, AstraZeneca, and Merck have expanded their companion diagnostic collaboration, to use BRACAnalysis CDx to identify germline BRCA mutations in…
DUBLIN–(BUSINESS WIRE)–The “Global Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.
AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.